Patent: 9,714,283

Summary for Patent: 9,714,283

Title:	Compositions and methods for the treatment of immunodeficiency
Abstract:	The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
Inventor(s):	Grossman; Adam S. (Saddle River, NJ), Grossman; Jerrold B. (Saddle River, NJ), Mond; James (Silver Spring, MD), Goldstein; Dov A. (New York, NY)
Assignee:	ADMA BIOLOGICS, INC. (Ramsey, NJ)
Application Number:	14/790,872
Patent Claims:	see list of patent claims

United States Patent 9,714,283: Immunoglobulin Pooling Metrics and Immunotherapy Claim Scope

What is the core inventive claim in US 9,714,283?

US 9,714,283 claims methods of immunotherapy where the active is immune globulin (IVIG-like or immune globulin preparations) prepared from plasma pools defined by quantitative immunologic performance metrics, then administered to a subject. The claim scope is built around a constrained pooling recipe:

• Pool size: pooled plasma composition from 1000 or more human plasma donors.
• RSV performance gate: pooled plasma has a final RSV neutralization titer of at least 1800.
• Comparative enhancement gate: pooled plasma has an antibody titer for selected respiratory pathogens that is at least 1.5x greater than the antibody titer in a control sample made from 1000 or more random donors.
• Donor composition restriction: less than 50% of donors used for pooling are from donors with final RSV neutralization titer at least 1800.
• Carrier: pharmaceutically acceptable carrier.
• Use cases expand by dependent claim subject selection and outcome endpoints (lung viral load reduction, histopathology reduction, viral RNA reduction in organs).

This is not a generic IVIG claim. It is a process-to-product-defined immune globulin claim where the “process definition” is expressed through pool immunology assays and donor selection distributions, then recited in a downstream method of administration.

How broad is independent claim 1?

Claim 1 is method of immunotherapy. It is broad on patient population only because dependent claims list many categories, while the independent claim itself is not restricted to disease state. Its breadth is governed by the specificity of the immune globulin pool definition.

Independent claim 1 requirements (all must be met)

1. Administer a therapeutically effective amount of an immunotherapeutic composition comprising:
   • A) Immune globulin prepared from pooled plasma that meets all of the following:
     • Pool size: ≥ 1000 donors.
     • RSV neutralization: final RSV neutralization titer ≥ 1800.
     • Cross-pathogen antibody uplift: for parainfluenza virus 1, parainfluenza virus 2, coronavirus OC43, coronavirus 229E, the pooled antibody titer is ≥ 1.5x the antibody titer in a control sample.
     • Control definition: control sample is a mixture from ≥ 1000 random donors.
     • Donor fraction rule: < 50% of donor plasmas used for pooling come from donors with RSV neutralization titer ≥ 1800.
   • B) Pharmaceutically acceptable carrier.
2. No explicit route, dose, formulation type, or patient eligibility is required in claim 1.

Built-in “precision” that narrows practical scope

The claim is narrow in manufacturing space even though it is wide in medical use:

• It requires a very specific quantitative relationship to a control sample (1.5x).
• It requires a specific donor composition rule (<50% high-RSV donors) while simultaneously requiring the pool to hit a high absolute RSV neutralization titer threshold (≥1800).
• It requires inclusion of immune globulin from pools with defined performance against multiple respiratory pathogens (in claim 1, the uplift must be for one or more selected pathogens among the four named viruses).

That structure aims to lock down a manufacturing approach that yields simultaneously high RSV neutralization and boosted antibodies against additional viruses.

Which dependent claims expand clinical scope vs. expand manufacturing scope?

Dependent claims split into two categories: (1) patient selection and (2) endpoint and additional antigen targets.

Clinical expansion (dependent claims 2-10)

• Claim 2: subject has immunodeficiency.
• Claim 3: subject has PIDD.
• Claim 4: subject categories include:
  • ESRD
  • immunosuppressive therapy
  • AIDS
  • diabetes
  • neonate
  • transplant
  • malfunctioning immune system
  • elderly
  • autoimmune disease
  • burn
  • cancer
  • acute care setting
• Claims 5-7: method outcomes:
  • reduces viral load in lungs
  • reduces lung histopathology
  • reduces level of pathogenic viral RNA in an organ
• Claim 8: organ can be lungs, liver, kidneys.
• Claims 9-10: treat infection; pathogens include RSV and additional viruses (parainfluenza 1/2, coronaviruses OC43/229E, influenza A/B, metapneumovirus).

Manufacturing expansion (dependent claims 11-19)

• Claim 11-13: immunotherapeutic composition may further include an anti-toxin agent; toxin can be botulinum, tetanus, E. coli toxin, C. difficile toxin, Vibrio RTX, staphylococcal toxins, cyanobacteria toxin, mycotoxins.
• Claims 14-18: composition can comprise neutralizing antibodies specific for:
  • Corynebacterium diphtheria
  • measles virus
  • polio virus
  • Haemophilus influenza
  • Streptococcus pneumonia
• Claim 19: combination across five neutralizing antibody specificities.

These dependent claims widen combinational product possibilities: the baseline immune globulin from RSV/cross-virus pooled plasma is not the sole actives.

Additional manufacturing variants (claims 20-22)

Claims 20-22 narrow the cross-virus uplift and specify which viruses must be uplifted:

• Claim 20: only 30-45% of donor plasma samples for pooling are from donors with RSV titer ≥ 1800 (a tighter donor fraction than “<50%” in claim 1).
• Claim 21: uplift must be for parainfluenza 1 and/or parainfluenza 2.
• Claim 22: uplift must be for coronavirus OC43 and/or coronavirus 229E.

How much room exists to design around claim 1?

Design-around is principally driven by the unique combination of (i) absolute RSV threshold, (ii) relative uplift vs control, and (iii) donor fraction rule.

Practical design-around levers

1. Miss the “≥1800 RSV neutralization titer” absolute threshold
   • If the pool final RSV neutralization titer is below 1800, claim 1’s pool definition fails.
2. Miss the “1.5x vs control sample” relative uplift
   • If the pooled antibody titer for the specified viruses is not at least 1.5x the control (prepared from 1000+ random donors), the claim fails even if absolute RSV neutralization is met.
3. Miss the donor fraction rule (<50% high-RSV donors)
   • Using 50% or more donors with RSV ≥1800 violates the claim’s composition constraint.
   • Claim 20 further narrows to 30-45%, so a competitor could target outside that tighter band while still potentially meeting the broader “<50%” structure in claim 1 only if they stay below 50%.
4. Change which pathogens are required
   • Claim 1 is tied to antibody uplift for “one or more” among parainfluenza 1, parainfluenza 2, coronavirus OC43, coronavirus 229E. A competitor could target a different viral set while still producing high RSV neutralization immune globulin.
5. Change formulation enough to avoid the “immune globulin prepared from pooled plasma” framing
   • If a competitor uses recombinant antibodies, synthetic cocktails, or donor-derived but non-immune globulin formats without the “immune globulin prepared from pooled plasma composition” definition, the literal scope contracts.

Litigation posture likely emphasized by the patentee

The claim is structured to make product characterization central:

• assay-based titer gates,
• assay-defined uplift relative to a control,
• donor fraction restrictions that are discoverable via manufacturing records.

That supports an enforcement strategy that does not require proving specific donor-by-donor identities, only whether the pool meets the defined assay and pooling composition rules.

What does the claim imply about the patent’s “center of gravity” in novelty?

The claim’s novelty thesis appears to be a pooling strategy that yields:

• high RSV neutralization (≥1800), while
• maintaining a constraint that fewer than half of donors are high-RSV donors (which implies “redistributing” antibody contribution across broader donor sets), and
• increasing antibody titers to additional respiratory pathogens (parainfluenza and coronaviruses) relative to a random-donor control.

From a patent-analytics perspective, the “inventive hook” is the coupling of:

• an RSV neutralization threshold,
• a comparative cross-virus uplift vs control,
• and a donor mix constraint.

That combination is uncommon in a typical IVIG patent landscape, which often claims general composition, broad neutralization, or manufacturing steps without tying to a relative uplift metric against a defined random-donor control.

How does claim 1 map to competitive product categories?

Potential infringement risk concentrates in products that look like:

• immune globulin preparations made from plasma pools with quantified neutralization performance,
• where the manufacturer can document a pool meeting the defined assay thresholds,
• and where the company benefits from cross-virus antibody uplift in the specified set.

Low risk categories include:

• recombinant monoclonals (no “immune globulin prepared from pooled plasma”),
• non-RSV targeted vaccines,
• hyperimmune globulin that does not use the “random control” uplift comparator,
• products that meet high RSV neutralization but do not demonstrate the 1.5x uplift for the specified viruses.

What is the patent landscape risk profile for US 9,714,283?

Because this patent is claim-locked to assay-defined plasma pooling, the landscape risk is tied to whether competitors also:

• define donor selection rules around high RSV titer donors,
• use large donor pools (≥1000),
• and quantify relative antibody uplift vs a defined random control sample.

In the US, enforcement risk is highest for companies producing next-generation hyperimmune or polyvalent immunoglobulins where manufacturing teams target multi-pathogen neutralization performance. Enforcement risk is moderate for standard IVIG if the claim-defined RSV threshold and the cross-virus uplift do not match.

In the absence of the patent’s full specification text and prosecution history, the practical analysis is limited to claim language: the patent’s enforcement hinge is measurement of the exact endpoints and the exact comparative framework.

Are the dependent claims likely to broaden or dilute enforceability?

Dependent claims 2-10 and 4-10 expand use cases and endpoints. They do not change the immune globulin pool definition of claim 1, but they may matter for:

• claim chart specificity (patient population framing and endpoints),
• whether accused products are positioned for infection indications and clinically measured outcomes.

Dependent claims 11-19 can increase commercial coverage (co-formulated anti-toxin or additional neutralizing antibodies) but can also introduce additional proof burdens if enforcement requires demonstrating those exact components are present in the accused immunotherapeutic composition.

Dependent claims 20-22 may be especially relevant in infringement because they introduce tighter numeric constraints:

• Claim 20’s 30-45% donor fraction band (a narrower manufacturing profile) can either help the patentee (if an accused manufacturer matches that band) or allow selective assertion if the broader <50% requirement is difficult to prove.

What claim elements are most vulnerable to invalidity attacks (high-level critical assessment)?

For US patentability and enforceability, the most vulnerable components are typically those that are:

• too abstract if not anchored in concrete process steps, or
• difficult to measure or reproduce reliably,
• or likely anticipated by prior immunoglobulin pooling approaches if those approaches already produced similar titer profiles and cross-pathogen uplift.

In this set of claims, “vulnerability points” are:

1. Assay-defined thresholds and comparative uplift
   • If prior art already disclosed pooling that yields comparable RSV titers and cross-virus antibody levels, claim 1 may be anticipated.
   • If prior art used similar comparator frameworks (even if not identical), obviousness risk rises.
2. Donor fraction limitations
   • If prior art already used donor selection strategies that exclude a portion of donors (creating high-titer pools) while still mixing enough donors to remain below a fraction threshold, claim novelty can weaken.
3. Lack of explicit step-by-step process in the claim
   • The claims define the pool by results and donor composition, but do not include detailed process steps beyond “immune globulin prepared from pooled plasma composition.” That can cut both ways: it aids breadth but increases invalidity risk if prior art has similar result-based pools.

Without the specification and file wrapper, the above remains a structural analysis of how claim language tends to be attacked rather than a claim-by-claim prior art mapping.

Key takeaways on enforceability and commercial strategy

• US 9,714,283 centers on assay-defined immune globulin from large plasma pools with an RSV neutralization threshold and relative cross-virus antibody uplift vs a defined random donor control.
• The sharpest infringement boundary is the combination of:
  • RSV neutralization ≥ 1800,
  • cross-virus uplift ≥ 1.5x vs control, and
  • <50% (or 30-45% in claim 20) high-RSV donors.
• Competitor design-around is most actionable by disrupting any one of those three gates.
• Dependent claims expand clinical indications and possible additional actives but remain downstream of the same immune globulin pool definition in claim 1.
• The patent landscape risk for manufacturers is highest where they produce polyvalent hyperimmune or enriched immunoglobulins and already manage donor selection to maximize RSV neutralization while maintaining large pools.

Key Takeaways

• Claim 1 is process-to-product for immune globulin defined by RSV neutralization (≥1800), comparative cross-virus antibody uplift (≥1.5x vs a random-donor control), and a donor fraction constraint (<50% RSV-high donors).
• Claims 20-22 tighten manufacturing parameters (30-45% donor fraction; specific virus subsets for uplift), enabling narrower enforcement when matched.
• Design-around is straightforward structurally: fail RSV threshold, fail 1.5x uplift vs control, or alter donor fraction to ≥50% or outside 30-45% (for claim 20).
• Clinical dependent claims expand use positioning (immunodeficiency, PIDD, multiple patient categories, and endpoints) without changing the pool definition.

FAQs

1) Does claim 1 require a specific route of administration or dosing regimen?

No. Claim 1 requires administering a therapeutically effective amount of the defined immune globulin composition, but it does not specify route or dosing schedule.

2) What is the most defining element of infringement risk?

Whether the accused immune globulin is prepared from a pooled plasma composition meeting all quantitative criteria: RSV neutralization ≥1800, cross-virus antibody uplift ≥1.5x vs a defined random-donor control, and donor fraction <50% with RSV-high titers.

3) Can a product with high RSV neutralization avoid infringement?

Yes, if it fails the 1.5x relative uplift requirement for parainfluenza 1/2 and/or coronaviruses OC43/229E (as recited for claim 1) or fails the donor fraction restriction.

4) Do dependent claims broaden the immunoglobulin definition?

Some dependent claims add optional components (anti-toxin agents; additional neutralizing antibodies), but the core immune globulin pooling definition remains anchored to claim 1’s structure (with tighter donor fraction and virus subset requirements in claims 20-22).

5) How do claims 20-22 affect strategy for both parties?

They create narrower target profiles. The patentee can assert a subset that better matches a specific accused manufacturing scheme, while competitors can align design changes to stay outside those tighter bands.

---

References

[1] United States Patent 9,714,283.

Details for Patent 9,714,283

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	May 21, 2004	9,714,283	2035-07-02
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	March 26, 2007	9,714,283	2035-07-02
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAGAM	immune globulin intravenous (human)	Injection	125062	July 11, 2014	9,714,283	2035-07-02
Adma Biologics, Inc.	BIVIGAM	immune globulin intravenous (human)	Injection	125389	December 19, 2012	9,714,283	2035-07-02

International Patent Family for US Patent 9,714,283

Country	Patent Number	Estimated Expiration
South Africa	201707303
World Intellectual Property Organization (WIPO)	2016069693
United States of America	9969793
United States of America	9815886